ClinicalTrials.gg
CompletedNCT06533982WOMEN-EX-MODUpdated Aug 1, 2024

Effect of Different Exercise Modalities on Cardiovascular and Cognitive Response in Postmenopausal Women

An interventional study of High intensity interval exercise session and Isometric neuromuscular exercise session in Menopause, Blood Pressure and Cognitive Decline, sponsored by University of Poitiers. Completed at 1 site in France. Open to female participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-01.

Sponsored by University of Poitiers · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 1 year 4 months after the study started (first participant enrolled Mar 2023, registered Jul 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 189 studies in Cognitive Dysfunction with a site in France — 52 open to participants now, 60 under way, 6 of them phase 3. Cognitive Dysfunction · France.

Enrollment
118th of 139
30 · median 88
Started
2023
with 9 others
No phase
104 of 189
32 open now
Registered
160th of 189
by date

Among the 189 studies in Cognitive Dysfunction with a site in France, this one is the 118th largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2023, is one of 104 with no phase, and was the 160th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

52 of the 189 studies in Cognitive Dysfunction with a site in France are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 45 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Cognitive Dysfunction with a site in France, or all of them as a file.
02

Study summary

Menopause is a natural stage in female aging, increasing cardiometabolic risk and making cardio-neuro-vascular disease (CNVD) the leading cause of mortality in women over 60. Declining ovarian hormones are linked to changes in body composition, increased blood pressure, and mild cognitive impairment. Menopause also often involves significant symptoms like menopausal vasomotor symptoms (VMS), affecting 60-80% of women for 5-10 years. Women with VMS exhibit a worse cardiovascular profile and greater cognitive decline.

Physical exercise is a promising non-pharmacological option to reduce CNVD risk and limit cognitive impairment in postmenopausal women, who have a 10-year window post-menopause during which physical activity benefits vascular and possibly neurovascular health. Studies link physical activity to lower cognitive decline and improved quality of life. However, optimal exercise modalities for managing CNVD risk in postmenopausal women remain undetermined.

Read the detailed description

Menopause is a natural stage in the female aging process, resulting in increased cardiometabolic risk, making cardio-neuro-vascular disease (CNVD) the leading cause of female mortality worldwide after the age of 60. Indeed, falling ovarian hormone concentrations are associated with altered body composition, increased blood pressure, as well as mild cognitive impairment.

For some women, menopause is also accompanied by symptoms that have a significant impact on their quality of life. Among these, menopausal vasomotor symptoms (VMS - hot flushes, night sweats...) are the most frequent, affecting 60% to 80% of women for an average of 5 to 10 years. Several studies have highlighted an altered cardiovascular profile (dyslipidemia, insulin resistance, pre-hypertension/hypertension...) and a more marked decline in cognitive performance in women with VMS.

In order to reduce the risk of CNVD and limit cognitive impairment, physical exercise appears to be a particularly interesting non-pharmacological management option for postmenopausal women. Indeed, the latter seem to present a 10-year post-menopausal time window, during which physical activity has a positive vascular and probably neurovascular effect, although the latter remains to be demonstrated. Numerous studies have also shown that physical activity is associated with a lower rate of cognitive decline, and improved quality of life.

However, to date, there is little evidence to determine which exercise modalities are most effective in managing the risk of CNVD in postmenopausal women.

The aims of this study:

  • To examine the effect of exercise on markers of cardio-neuro-vascular health and cognition in postmenopausal women.
  • Second, to compare the differences in the cardio-neuro-vascular and cognitive response to exercise, dependent on the type of exercise, the physical fitness and the presence of menopausal symptoms.
  • Third, to examine the effect of menopausal symptoms, and physical fitness on cardio-neuro-vascular health markers and cognitive health markers.
03

Conditions studied

  • Menopause
  • Blood Pressure
  • Cognitive Decline

Keywords

  • Physical exercise
  • High intensity interval exercise
  • Handgrip
04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Menopausal women (absence of menstruation for 12 consecutive months) for less than 10 years
  • Women with or without vasomotor symptoms
  • Women covered by the French Social Security system

Exclusion criteria

Exclusion Criteria:

  • Surgical menopause (oophorectomy)
  • Premature ovarian failure
  • Chronic renal failure
  • Respiratory pathology (unstable asthma, respiratory insufficiency or pulmonary hypertension)
  • Cardiovascular disease (coronary, valvular, hypertrophic, hypertensive, infiltrative, constrictive or rhythmic)
  • Medically treated hypertension
  • Severe obesity ( > 40 kg/m²)
  • Hearing or vision problems that prevent reading or distinguishing colors
  • Recent (\< 1 year) central neurological or psychiatric disorders
  • Moderate to severe cognitive impairment ( \< 18).
  • Judicial protection or guardianship
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    High intensity interval exercise session

    Performed on an ergometer, the intensity of the session is adapted to the participant's physical capacity, initially assessed by the VO2max test at baseline. The session begins with a 5-minute warm-up at 50% of maximum aerobic power (MAP). The exercise then consists of 2 sets of 12 repetitions of 15 seconds each at 100% of MAP and 15 seconds of passive recovery. 2-minute of passive recovery is recommended between the two sets. The session ends with 5-minute of recovery at 50% of MAP.

    Other: High intensity interval exercise session

  • Experimental
    Isometric neuromuscular exercise session

    Performed with a handgrip (K-Force grip, KINVENT), the intensity of the session is adapted to the participant's capacity, initially assessed by the isometric maximal voluntary force (MVF) measurement at the beginning of the session. The session consists of 4 repetitions of 2 minutes at 30% of the isometric MVF, separated by 1 minute recovery.

    Other: Isometric neuromuscular exercise session

  • No intervention
    Control session

    Participants are seated for 30 minutes.

Interventions

  • OtherHigh intensity interval exercise session

    Physical activity session supervised and adapted on ergometer

  • OtherIsometric neuromuscular exercise session

    Physical activity session supervised and adapted with a handgrip

06

What researchers measure

Primary outcomes

  1. Systolic and diastolic blood pressure (ambulatory blood pressure measurement)

    Post-exercise hypotension, using the Mobil-O-Graph (mmHg).

    Time frame: After sessions (24 hours)

  2. Systolic and diastolic blood pressure (resting)

    Automated oscillometric tensiometer (mmHg).

    Time frame: Before and after sessions (15 minutes)

Secondary outcomes

  1. Concentration of cerebral oxygenation

    Near-infrared spectroscopy is used to measure concentrations of oxygenated and desoxygenated hemoglobin (µmol/L).

    Time frame: Before, during, and after sessions (1 hour)

  2. Working memory

    2-back task (scored from 0 to 28, higher scores indicate better working memory).

    Time frame: Before and after sessions (10 minutes)

  3. Episodic memory

    Memory scale III (MEM-III), a story recall task taken from the test battery in the Wechsler-Memory Scale-Revised (scored from 0 to 25, higher scores indicate better episodic memory).

    Time frame: Before and after sessions (15 minutes)

  4. Executive function

    Stroop task, used to assess inhibitory control (scored as a ratio, negative score indicates worse inhibitory control vs. positive score indicates better inhibitory control).

    Time frame: Before and after sessions (15 minutes)

  5. Perception of exertion

    Modified Borg scale (scored 0 to 10, higher score indicates lower exercise tolerance).

    Time frame: After sessions (1 minute)

  6. Endothelial function (brachial artery dilation capacity)

    At rest, the flow-mediated dilatation technique is used with high-resolution Doppler ultrasound (CX-50 Philipps).

    Time frame: Baseline (30 minutes)

  7. Baroreflex sensitivity

    At rest, baroreflex sensitivity is measured using the Finapres.

    Time frame: Baseline (1 hour)

  8. Aortic systolic and diastolic blood pressure

    At rest, using the SphygmoCor device, which measures central blood pressure (mmHg).

    Time frame: Baseline (15 minutes)

  9. Arterial stiffness (pulse wave velocity)

    At rest, using the SphygmoCor device, which calculates carotid-femoral pulse wave velocity (m/s).

    Time frame: Baseline (15 minutes)

  10. Physical fitness

    Maximal cardiopulmonary effort test (VO2max).

    Time frame: Baseline (30 minutes)

  11. Blood lipid concentrations

    Total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides (g/L).

    Time frame: Baseline (5 minutes)

  12. Blood hormone concentrations

    Progesterone, 17-beta-estradiol, and follicle-stimulating hormone (ng/L).

    Time frame: Baseline (5 minutes)

  13. Body weight

    Total body weight, fat mass, fat-free mass and visceral-fat mass in kilograms using the Tanita impedance scale.

    Time frame: Baseline (1 minute)

  14. Body composition

    Percentage of body fat and fat-free mass using the Tanita impedance scale.

    Time frame: Baseline (1 minute)

  15. Height

    Height in meters measured with a height gauge.

    Time frame: Baseline (1 minute)

  16. Body mass index

    Calculated from total body weight and height (kg/m²).

    Time frame: Baseline (1 minute)

  17. Cognitive assessment

    Montreal Cognitive Assessment (MoCA) test (scored from 0 to 30, with higher scores indicating better cognitive function).

    Time frame: Baseline (15 minutes)

  18. Menopausal rating scale

    Composed of 11 items rating the severity of menopausal symptoms from 0 (no symptoms) to 4 (very severe).

    Time frame: Baseline (15 minutes)

  19. Hot flash related daily interference scale

    Composed of 10 items scored from 0 (no impact) to 10 (completely interferes), evaluating the impact of vasomotor symptoms on daily life.

    Time frame: Baseline (15 minutes)

  20. Hospital Anxiety and Depression Scale

    It provides two scores ranging from 0 to 21 that quantify anxiety and depression. Higher scores indicate more severe symptoms.

    Time frame: Baseline (15 minutes)

  21. Global physical activity questionnaire

    Physical activity and sedentary time assessed using the Global Physical Activity Questionnaire. Higher scores indicate better physical activity levels (categorized into high, moderate, and low physical activity levels).

    Time frame: Baseline (15 minutes)

  22. Daily tobacco and alcohol use

    Use daily or not use.

    Time frame: Baseline

  23. Age

    Age, age at menarche and menopause (in years).

    Time frame: Baseline

  24. Educational level

    Secondary education, high school graduate, bachelor's degree, master's or doctoral degree.

    Time frame: Baseline

  25. Number of children

    Self-reported.

    Time frame: Baseline

07

Study locations

1 site
  • Faculty of Sport Science - MOVE Laboratory (UR20296)
    Poitiers, 86000, France
08

References and documents

Publications

  • Armas Rojas N, Dobell E, Lacey B, Varona-Perez P, Burrett JA, Lorenzo-Vazquez E, Calderon Martinez M, Sherliker P, Bess Constanten S, Morales Rigau JM, Hernandez Lopez OJ, Martinez Morales MA, Alonso Aloma I, Achiong Estupinan F, Diaz Gonzalez M, Rosquete Munoz N, Cendra Asencio M, Peto R, Emberson J, Duenas Herrera A, Lewington S. Burden of hypertension and associated risks for cardiovascular mortality in Cuba: a prospective cohort study. Lancet Public Health. 2019 Feb;4(2):e107-e115. doi: 10.1016/S2468-2667(18)30210-X. Epub 2019 Jan 23. Erratum In: Lancet Public Health. 2019 Feb;4(2):e88. doi: 10.1016/S2468-2667(19)30004-0. PubMed 30683584 ↗
  • Greendale GA, Sternfeld B, Huang M, Han W, Karvonen-Gutierrez C, Ruppert K, Cauley JA, Finkelstein JS, Jiang SF, Karlamangla AS. Changes in body composition and weight during the menopause transition. JCI Insight. 2019 Mar 7;4(5):e124865. doi: 10.1172/jci.insight.124865. eCollection 2019 Mar 7. PubMed 30843880 ↗
  • Boyle CP, Raji CA, Erickson KI, Lopez OL, Becker JT, Gach HM, Kuller LH, Longstreth W Jr, Carmichael OT, Riedel BC, Thompson PM. Estrogen, brain structure, and cognition in postmenopausal women. Hum Brain Mapp. 2021 Jan;42(1):24-35. doi: 10.1002/hbm.25200. Epub 2020 Sep 10. PubMed 32910516 ↗
  • Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, Thurston RC; Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015 Apr;175(4):531-9. doi: 10.1001/jamainternmed.2014.8063. PubMed 25686030 ↗
  • Zhu D, Chung HF, Dobson AJ, Pandeya N, Anderson DJ, Kuh D, Hardy R, Brunner EJ, Avis NE, Gold EB, El Khoudary SR, Crawford SL, Mishra GD. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies. Am J Obstet Gynecol. 2020 Dec;223(6):898.e1-898.e16. doi: 10.1016/j.ajog.2020.06.039. Epub 2020 Jun 23. PubMed 32585222 ↗
  • Gliemann L, Hellsten Y. The exercise timing hypothesis: can exercise training compensate for the reduction in blood vessel function after menopause if timed right? J Physiol. 2019 Oct;597(19):4915-4925. doi: 10.1113/JP277056. Epub 2019 Jun 30. PubMed 31077368 ↗
  • Anderson D, Seib C, Rasmussen L. Can physical activity prevent physical and cognitive decline in postmenopausal women? A systematic review of the literature. Maturitas. 2014 Sep;79(1):14-33. doi: 10.1016/j.maturitas.2014.06.010. Epub 2014 Jun 20. PubMed 25008420 ↗
  • Hybholt M. Psychological and social health outcomes of physical activity around menopause: A scoping review of research. Maturitas. 2022 Oct;164:88-97. doi: 10.1016/j.maturitas.2022.07.014. Epub 2022 Aug 3. PubMed 35964395 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Mar 2023, 0 months.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 0 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2024
First posted
Aug 1, 2024
StartActual
Mar 10, 2023
Primary completionActual
Mar 28, 2023
CompletionActual
Dec 20, 2023
Last update
Aug 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06533982
Lead sponsor
University of Poitiers
Responsible party
Laurent Bosquet (Director, University of Poitiers) — Principal investigator
First posted
Aug 1, 2024
Start date
Mar 10, 2023
Primary completion
Mar 28, 2023
Completion
Dec 20, 2023
Last update
Aug 1, 2024

Study contacts

Laurent Bosquet, Pr
principal investigator · University of Poitiers - Faculty of Sport Science - MOVE Laboratory (UR20296)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion